These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

828 related articles for article (PubMed ID: 24007863)

  • 1. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
    Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
    Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
    Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation.
    Wang H; Shi B; Zhang Q; Jiang H; Hu S; Kong J; Yao M; Yang S; Li Z
    FASEB J; 2012 Jan; 26(1):73-80. PubMed ID: 21917986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Yang Y; Jiang H; Gao H; Kong J; Zhang P; Hu S; Shi B; Zhang P; Yao M; Li Z
    Neoplasia; 2012 Jun; 14(6):509-18. PubMed ID: 22787432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts].
    Jin CD; Yamamoto T; Nakamura M; Arai I; Kishin R; Xing X; Nagano H; Dono K; Umeshita K; Nakamori S; Sakon M; Monden M
    Gan To Kagaku Ryoho; 2004 Oct; 31(10):1511-5. PubMed ID: 15508442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma.
    Wang H; Jiang H; Zhou M; Xu Z; Liu S; Shi B; Yao X; Yao M; Gu J; Li Z
    Cancer Lett; 2009 Jun; 279(1):30-8. PubMed ID: 19217205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III.
    Jiang H; Wang H; Tan Z; Hu S; Wang H; Shi B; Yang L; Li P; Gu J; Wang H; Li Z
    J Biol Chem; 2011 Feb; 286(7):5913-20. PubMed ID: 21163950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
    Ischenko I; Camaj P; Seeliger H; Kleespies A; Guba M; De Toni EN; Schwarz B; Graeb C; Eichhorn ME; Jauch KW; Bruns CJ
    Oncogene; 2008 Dec; 27(57):7212-22. PubMed ID: 18794807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Itashiki Y; Harada K; Ferdous T; Yoshida H
    Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Water extract of Hedyotis Diffusa Willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibiting the CDK2-E2F1 pathway.
    Chen XZ; Cao ZY; Chen TS; Zhang YQ; Liu ZZ; Su YT; Liao LM; Du J
    Oncol Rep; 2012 Aug; 28(2):742-8. PubMed ID: 22641337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
    Yanase K; Yoshiji H; Ikenaka Y; Noguchi R; Kitade M; Kaji K; Yoshii J; Namisaki T; Yamazaki M; Asada K; Tsujimoto T; Akahane T; Uemura M; Fukui H
    Oncol Rep; 2007 Feb; 17(2):441-6. PubMed ID: 17203185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
    Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma.
    Hu XY; Liang JY; Guo XJ; Liu L; Guo YB
    Clin Exp Pharmacol Physiol; 2015 Feb; 42(2):146-53. PubMed ID: 25363523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro.
    Nakamura M; Nagano H; Sakon M; Yamamoto T; Ota H; Wada H; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Dono K; Monden M
    J Hepatol; 2007 Jan; 46(1):77-88. PubMed ID: 17045692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suberoylanilide hydroxamic acid enhances chemosensitivity to 5-fluorouracil in hepatocellular carcinoma via inhibition of thymidylate synthase.
    Liao B; Liang H; Chen J; Liu Q; Zhang B; Chen X
    Tumour Biol; 2015 Dec; 36(12):9347-56. PubMed ID: 26108995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of and Mechanism Underlying Autophagy in Hepatocellular Carcinoma Induced by CH12, a Monoclonal Antibody Directed Against Epidermal Growth Factor Receptor Variant III.
    Xu W; Song F; Wang B; Li K; Tian M; Yu M; Pan X; Shi B; Liu J; Gu J; Li Z; Jiang H
    Cell Physiol Biochem; 2018; 46(1):226-237. PubMed ID: 29587298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor efficacy of sequential treatment with docetaxel and 5-fluorouracil against human oral cancer cells.
    Tamatani T; Ferdous T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Nagai H; Fujisawa K; Miyamoto Y
    Int J Oncol; 2012 Sep; 41(3):1148-56. PubMed ID: 22766915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
    Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
    Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.